DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,888,996 Farb (45) Date of Patent: Mar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,888,996 Farb (45) Date of Patent: Mar USOO5888996A United States Patent (19) 11 Patent Number: 5,888,996 Farb (45) Date of Patent: Mar. 30, 1999 54 INHIBITION OF NMDA RECEPTOR Gyermek, L., et al., “Structure-Activity Relationship of ACTIVITY AND MODULATION OF Some Steroidal Hypnotic Agents,” Steroids. CCX, GLUTAMATE-MEDIATED SYNAPTC 11:117–125 (1968). ACTIVITY Wu, F.-S., et al., “Pregnenolone Sulfate: A Positive Allos teric Modulator at the N-Methyl-D-aspartate Receptor,” 75 Inventor: David H. Farb, Cambridge, Mass. Molecular Pharmacology, 40:333-336 (1991). 73 Assignee: Trustees of Boston University, Boston, Park-Chung, M., et al., “3C-Hydroxy-5B-pregnan-20-one Mass. Sulfate: A Negative Modulator of the NMDA-Induced Cur rent in Cultured Neurons,” Molecular Pharmacology, 21 Appl. No.: 559,442 46:146-150 (1994). Wieland, S., et al., “Anxiolytic Activity of the Progesterone 22 Filed: Nov. 15, 1995 Metabolite 5C-pregnan-3C-ol-20-one,” Brain Research, Related U.S. Application Data 565:263-268 (1991). Belelli, D., et al., “Anticonvulsant Profile of the Progester 63 Continuation-in-part of Ser. No. 507,757, Jul. 26, 1995, one Metabolite 5C-pregnan-3C-ol-20-one.” European abandoned. Journal of Pharmacology, 166:325–329 (1989). (51) Int. Cl." ..................................................... A61K 31/56 Lan, N. C., et al., “Neurocactive Steroid Actions at the 52 U.S. Cl. .......................... 514/182; 514/177; 514/178; GABA Receptor.” Hormones and Behavior; 28:537-544 514/179 (1994). 58 Field of Search ..................................... 514/182, 177, 514/178, 179 Primary Examiner Rebecca Cook Attorney, Agent, or Firm-Hamilton, Brook, Smith & 56) References Cited Reynolds, P.C. U.S. PATENT DOCUMENTS 57 ABSTRACT 5,212,167 5/1993 Farb ........................................ 514/178 5,366,968 11/1994 Farb ........................................ 514/178 The present invention relates to a method of inhibiting N-methyl-D-aspartate (NMDA) glutamate receptor FOREIGN PATENT DOCUMENTS mediated ion channel activity (NMDA receptor activity), WO 93/04687 4/1991 WIPO. comprising contacting a neuronal cell (e.g., hippocampal WO 93/05786 4/1993 WIPO. neuron, Spinal cord cell) with an effective amount (e.g., 1 to WO 94/27608 12/1994 WIPO. 500 uM) of a derivative of pregnenolone sulfate. Derivatives of pregnenolone sulfate that inhibit NMDA receptor activity OTHER PUBLICATIONS include pregnenolone Sulfate in which the A ring includes at CA 122:23982 Irwinet et al., 1994. least one double bond or is fully unsaturated, the double CA 121:125584 Park-Chung et al., 1994. bond at the C5-C6 position is reduced, the moiety at the C3, CA 119:86563 Bowlby, 1993. C10, C11 or C13 position is modified, alone or in combi CA 119:20512 Farb, Mar. 18, 1993. nation. It further relates to pregnenolone Sulfate derivatives CA 117:185114 Malone, 1992. which have modifications at other positions (e.g., C5, C7, Wong, M., and Moss, R.L., “Patch-Clamp Analysis of C10, C16, C17, C18, C19, C20, C21), alone or in Direct Steroidal Modulation of Glutamate Receptor-Chan combination, and are inhibitors of NMDA recepteor activity. nels”, Jour: of Neuroendocrinology, 6:347–355, (1994). The pregnenolone Sulfate derivatives differ from preg Bowlby, M.R., “Pregnenolone Sulfate Potentiation of nenolone Sulfate at least one position. The present invention N-Methyl-D-aspartate Receptor Channels in Hippocampal also relates to a method of modulating or altering (e.g., Neurons”, Mol. Pharmacol., 43(5):813–819, (1993). potentiating; inhibiting) excitatory glutamate-mediated Syn Irwin, R. P., et al., “Steroid Potentiation and Inhibition of aptic activity comprising contacting neurons with preg N-Methyl-D-Aspartate Receptor-Mediated Intracellular nenolone Sulfate and derivatives of pregnenolone Sulfate. Ca++ Responses: Structure-Activity Studies,” J. Pharm. and Experimental Therapeutics, 271(2):677-682 (1994). 17 Claims, 5 Drawing Sheets U.S. Patent Mar. 30, 1999 Sheet 1 of 5 5,888,996 CH3 CH3 C=O CO OSO Osc-O Pregnanolone CH Sulfate ?2 CH3 CH2 C=O o2 so Pregnanalone hemisu CCindte O 3SO 3CI-Hydroxy-5B-pregnan-2O-One Sulfate (pregnanolone Sulfate) 5B3CIS CH CH3 C C=O Osc O CH2 OSO CH2 3 H oCo 3B-Hydroxy-5B-pregnan-20- 17 B-estradio-3- One Sulfote he misuCCinCte 5B3 BS O2SO3 CH3 AndrosterOne Sulfote - CH C=O '3 HO C= O O3SO OSO | B-OH-pregnanolone 3 H Sulfate 3CI-Hydroxy-5CI-pregnan-2O One Sufote 5C3O. FG. U.S. Patent Mar. 30, 1999 Sheet 2 of 5 5,888,996 A NMDA 5B3CISNMDAt 5B3CIS NMDA . OOpA OS B K 5B3OSK+5B3CIS K i. 4OOJA OS C AMPA 5B3CIS AMPA+5B3CIS AMPA 25OJA OS FG. 2 U.S. Patent Mar. 30, 1999 Sheet 3 of 5 5,888,996 - Of O-6 IO-5 O-4 O-3 O-2 (5B3CIS) M FG. 3 U.S. Patent Mar. 30, 1999 Sheet 4 of 5 5,888,996 KX 5B3CIS (OOM 5B3CHS IOOM E2 HS2OOM Spino Cord rot hippocompo Electrophysiology 3Ou MNMDA FG. 4 U.S. Patent Mar. 30, 1999 Sheet 5 of 5 5,888,996 OO |: Chronic ShOrt term 25 JM NMDA 3OJM NMDA 24 hrs 5 min NMDA excitotoxicity F.G. 5 5,888,996 1 2 INHIBITION OF NMDA RECEPTOR include pregnenolone Sulfate derivatives in which the A ring ACTIVITY AND MODULATION OF includes at least one double bond or is fully unsaturated, GLUTAMATE-MEDIATED SYNAPTC pregnenolone sulfate derivatives in which the double bond at ACTIVITY the C5-C6 position is reduced, pregnenolone Sulfate in which the moiety at the C3, C10, C11 or C13 position is RELATED APPLICATIONS modified, alone or in combinations thereof. It further relates This application is a Continuation-in-Part application of to pregnenolone Sulfate derivatives which have modifica U.S. application Ser. No. 08/507,757, filed Jul. 26, 1995, tions at other positions (e.g., C5, C7, C10, C16, C17, C18, abandoned, entitled “Inhibition of NMDA Receptor Activ C19, C20, C21), alone or in combination, and are inhibitors ity” by David H. Farb, which claims priority to U.S. Pro of NMDA receptor activity. The pregnenolone sulfate visional Application, 60/001,439, filed on Jul. 24, 1995, derivatives differ from pregnenolone Sulfate at least one entitled “3C-Hydroxy-5B-Pregnan-20-One Sulfate: A Nega position. tive Modulator of the NMDA-Induced Current in Cultured In one embodiment the present invention relates to a method for inhibiting NMDA glutamate receptor mediated Neurons” by David H. Farb and claims the benefit thereof. 15 ion-channel activity comprising contacting a neuronal cell FUNDING with an effective amount of a derivative of pregnenolone Sulfate wherein the derivative is Selected from the group Work described herein was funded by grants from the consisting of 3C-hydroxy-5B-pregnan-20-one Sulfate National Institutes of Mental Health (Grant MH-49469). (5 B3CS), 3B-hydroxy-5E-pregnan-20-one sulfate (5 B3 BS), The United States government has certain rights in the 3C-hydroxy-5C.-pregnan-20-one sulfate (50.3C.S), invention. 3.C.-hydroxy-5C.-pregnan-20-one he misuccinate (5f.3C. he misuccinate), 17 B-estradiol hemisuccinate, 11 f-OH BACKGROUND pregnenolone Sulfate and androsterone Sulfate. L-Glutamate is thought to be the major excitatory neu The present invention also relates to a method of inhib rotransmitter in the vertebrate central nervous System and is 25 iting toxic effects associated with activation of the NMDA known to activate at least three major, pharmacologically receptor in neurons (e.g., hippocampal neurons, Spinal cord distinct classes of glutamate-gated ion channels: N-methyl cells), comprising contacting the neurons with a derivative D-aspartate (NMDA), C.-amino-3-hydroxy-5-methyl-4- of pregnenolone Sulfate Selected from the group consisting isoxazole-propionate (AMPA), and kainate receptors. These of: 533Cs, 5B3 Bs, 5C3Cs, 5B3C. hemisuccinate, 17B three inotropic receptors are named according to their Selec estradiol hemisuccinate, 11B-OH-pregnenolone Sulfate and tive agonists. androsterone Sulfate. NMDA receptors have attracted particular attention Thus, the ability to selectively inhibit the NMDA receptor because of their importance in normal brain function and in acroSS nerve cell membranes offers the means for pharma pathophysiological conditions Such as epilepsy and cerebral cological intervention in various glutamate-induced condi ischemia (Rothman, S. M. and Olney, J. W., Trends 35 tions Such as excitotoxicity, epilepsy, cerebral ischemia and Neurosci., 10:299-302 (1987)). The NMDA receptor Stroke. appears to be essential for the induction of long-term poten The present invention also relates to a method of modul tiation (Collingridge, G. L. and Bliss, T. V. P., Trends lating or altering (e.g., potentiating; inhibiting) excitatory Neurosci., 10:288-293 (1987)), a proposed underlying 40 glutamate-mediated Synaptic activity comprising contacting mechanism for learning and memory (Madison, D. V., et al., neuronal cells with pregnenolone Sulfate or a derivative of Annu. Rev. Neurosci., 14:379-397 (1991)), ischemic cell pregnenolone Sulfate. In one embodiment, the invention death, epilepsy, and other neurological disorders (Simon, R. relates to a method of potentiating excitatory glutamate P., et al., Science 226:850-852 (1984); Choi, D. W., J. mediated Synaptic activity comprising contacting neuronal Neurosci. 10:2493-2501 (1990) such as hypoxic neuronal cells with pregnenolone Sulfate or a derivative of preg damage (Simon, R., et al., Science, 226:850-852 (1984)), 45 nenolone Sulfate (e.g., dehydroepiandrosterone Sulfate). In Schizophrenia (Carlsson, M., et al., Trends NeuroSci., another embodiment, the invention relates to a method of 13:272-276 (1990); Watchel, H., et al., Trends Pharmacol. inhibiting excitatory glutamate-mediated Synaptic activity Sci., 11:219–220 (1990)) and excitotoxicity (Onley, J., et al., comprising contacting neuronal cells with a derivative of Brain Res., 221:207-210 (1981)). The integral channel of 50 pregnenolone Sulfate (e.g. 5(33CS). the NMDA receptor is permeable to Na+, K+, and Ca".
Load more

Recommended publications
  • Download Product Insert (PDF)
    Product Information CNQX Item No. 14618 CAS Registry No.: 115066-14-3 Formal Name: 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-6- quinoxalinecarbonitrile H Synonyms: 6-cyano-7-Nitroquinoxaline-2,3-dione, NC N O FG 9065 MF: C9H4N4O4 FW: 232.2 O O N N Purity: ≥98% 2 Stability: ≥2 years at -20°C H Supplied as: A crystalline solid λ UV/Vis.: max: 217, 275, 315 nm Laboratory Procedures For long term storage, we suggest that CNQX be stored as supplied at -20°C. It should be stable for at least two years. CNQX is supplied as a crystalline solid. A stock solution may be made by dissolving the CNQX in the solvent of choice. CNQX is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CNQX in these solvents is approximately 5 and 12 mg/ml, respectively. CNQX is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CNQX should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CNQX has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. CNQX is a competitive, non-NMDA glutamate receptor antagonist (IC50s = 0.3 and 1.5 μM for AMPA and kainate 1,2 receptors, respectively, versus IC50 = 25 μM for NMDA receptors). This compound has been used to specifically target AMPA and kainate receptor responses and thus differentiate from that of NMDA receptors.
    [Show full text]
  • An Investigation Into Pro-Apoptotic Targets in Experimental Glaucoma and the Neuroprotective Effects of Ginkgo Biloba in Retinal Ganglion Cells
    An investigation into pro-apoptotic targets in experimental glaucoma and the neuroprotective effects of Ginkgo biloba in retinal ganglion cells Abeir Baltmr MB ChB, FRCS (Glasg) A thesis submitted to University College London for the degree of Doctor of Medicine (Research) 2012 Glaucoma and Retinal Neurodegeneration Research Group Visual Neuroscience Institute of Ophthalmology 1 Declaration I, Abeir Baltmr, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Abeir Baltmr 2 Abstract Ginkgo biloba has been advocated as a neuroprotective agent for several years in glaucoma. In this study, immunohistochemistry was used to identify known potential molecular targets of Ginkgo biloba related to retinal ganglion cell (RGC) apoptosis in experimental glaucoma, including amyloid precursor protein (APP), Aß, cytochrome c, caspase-3 and tumor necrosis factor receptor-1 (TNF-R1). Furthermore, using apoptotic inducers related to mechanisms implicated in glaucoma, namely Dimethyl sulphoxide (DMSO), ultraviolet C (UVC) and Sodium Azide (NaN3), the effects of the terpenoid fraction of Ginkgo biloba (Ginkgolide A, Ginkgolide B and Bilobalide) were investigated separately in cultured retinal ganglion cells (RGC-5). Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and morphological analysis of DMSO treated RGC-5 was performed using Hoechst 33342 stain. Immunohistochemistry showed a strong inverse correlation between Aß and APP in ocular hypertension (OHT) animals, with APP and Aß accumulation peaking at 1 and 12 weeks after intraocular pressure (IOP) elevation respectively. Cytochrome c and TNF-R1 expression peaked at 3 weeks, and active caspase 3 activity at 12 weeks after IOP elevation.
    [Show full text]
  • Synthesis and Biological Evaluation
    Margarida Leonor Florindo Espadinha Licenciatura em Química Aplicada Enantiopure bicyclic lactams: synthesis and biological evaluation Dissertação para obtenção do Grau de Mestre em Química Bioorgânica Orientador: Prof. Doutora Maria M. M. Santos, FF-UL Elemento de Ligação: Prof. Doutora Paula Sério Branco, FCT-UNL Presidente: Prof. Doutora Paula Sério Branco, FCT-UNL Arguente: Prof. Doutor Vasco Bonifácio, IST-CQFM Vogal: Prof. Doutora Maria M. M. Santos, FF-UL Outubro 2015 i LOMBADA biological evaluation biological dinha synthesis and and synthesis : Margarida Espa Margarida lactams bicyclic Enantiopure ii 2015 Margarida Leonor Florindo Espadinha Licenciatura em Química Aplicada Enantiopure bicyclic lactams: synthesis and biological evaluation Dissertação para obtenção do Grau de Mestre em Química Bioorgânica Orientador: Prof. Doutora Maria M. M. Santos, FF-UL Elemento de Ligação: Prof. Doutora Paula Sério Branco, FCT Presidente: Prof. Doutora Paula Sério Branco, FCT-UNL Arguente: Doutor Vasco Bonifácio, IST-CQFM Vogal: Prof. Doutora Maria M. M. Santos, FF-UL Outubro 2015 iii Enantiopure bicyclic lactams: synthesis and biological evaluation Margarida Leonor Florindo Espadinha, Copyright A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por outro qualquer meio conhecido ou que venha a ser inventado e de divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor. iv Acknowledgements I would like to thank Professor Dr. Maria M.
    [Show full text]
  • 1750.Full.Pdf
    1750 • The Journal of Neuroscience, February 3, 2010 • 30(5):1750–1759 Development/Plasticity/Repair In the Developing Rat Hippocampus, Endogenous Activation of Presynaptic Kainate Receptors Reduces GABA Release from Mossy Fiber Terminals Maddalena D. Caiati,* Sudhir Sivakumaran,* and Enrico Cherubini Neuroscience Programme, International School for Advanced Studies, 34014 Trieste, Italy Presynaptic kainate receptors regulate synaptic transmission in several brain areas but are not known to have this action at immature mossy fiber (MF) terminals, which during the first week of postnatal life release GABA, which exerts into targeted cells a depolarizing and excitatory action. Here, we report that, during the first week of postnatal life, endogenous activation of GluK1 receptors by glutamate present in the extracellular space severely depresses MF-mediated GABAergic currents [GABAA-mediated postsynaptic currents (GPSCs)]. Activation of GluK1 receptors was prevented by treating the slices with enzymatic glutamate scavengers that enhanced the clearance of glutamate from the extracellular space. The depressant effect of GluK1 on MF-GPSCs was mediated by a metabotropic process sensitive to pertussis toxin. In the presence of U73122 (1-[6-[[(17b)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H- pyrrole-2,5-dione), a selective inhibitor of phospholipase C, along the transduction pathway downstream to G-protein, GluK1 activation increased the probability of GABA release, thus unveiling the ionotropic action of this receptor. In line with this type of action, we found that GluK1 enhanced MF excitability by directly depolarizing MF terminals via calcium-permeable cation channels. Furthermore, GluK1 dynamically regulated the direction of spike time-dependent plasticity occurring by pairing MF stimulation with postsynaptic spiking and switched spike time-dependent potentiation into depression.
    [Show full text]
  • Qt267353tc Nosplash 6C08d1b
    Copyright 2011 by Leslie Ann Cruz ii In Memoriam Andrew Braisted (1963-2003) Warren DeLano (1972-2009) Two of the best scientists that I had the opportunity work with at Sunesis Pharmaceuticals. So much talent. Gone too soon… iii Dedication To my husband, George, and my son, Thomas My two most favorite men. To the grandfather I never had: Dr. David T. Petty, my life-long mentor To My Family and Friends who have supported and encouraged me throughout the years: Mom, Jim, Dad, Mikey, Maria, Lyla Carolyn, Bob, Melissa, Rob, LeeAnn, Graciela, James David, Janell, Lori, Becky, Judy, Alex, Gigi Daniel, Astrid, Dave, Scott, Joice, Kwasi, Marcus Dan and Monya Jeanne and Bruce iv Acknowledgments The saying goes, “It takes a village to raise a child”. It also takes a village to raise a scientist. Thank You to All My Teachers and Mentors With Special Thanks To: St. Benedict's Elementary School Ilene Hopkins Memorial Jr. High School Timothy Sandow Thornton Fractional South High School Richard Powell and Ann Rice The University of Chicago Viresh Rawal Argonne National Laboratory John Hryn v MediChem Research Raghu Samy, Stuart Feinberg, Shankar Saha, Dimitry Kolton Sunesis Pharmaceuticals Andrew Braisted, Dan Erlanson, Jeanne Hardy, Doug Cary, Brian Cunningham, Brian Raimundo, Molly He, Michelle Arkin, Darin Allen, Warren DeLano, Jim Wells University of California, San Francisco My Adviser: Robert Fletterick, My Dissertation Committee: Holly Ingraham, Jack Taunton, My Orals Committee: Pam England, Jim Wells, Lily Jan, Kevan Shokat Chris Olson, Charly Craik, Tom Scanlan, Kip Guy, Sue Miller, Dave Agard, Bob Stroud, David Julius, Roger Nicoll, Maia Vinogradova, Fumiaki Yumoto, Phuong Nguyen, Sam Pfaff, Eric Slivka, Jeremey Wilbur, Cindy Benod, Kris Kuchenbecker, Peter Huang, Elena Sablin, Ulrike Boettcher, Kristin Krukenburg, James Kraemer, Mariano Tabios, Rebeca Choy Collaborators Marc Cox, Eva Estébanez-Perpiñá, Paul Webb, John Baxter, Stephen Mayo vi Preface My dissertation is comprised of the two projects I worked on during my graduate career.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. U M I films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send U M I a complete manuscript and there are missing pages, these w ill be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact U M I directly to order. University Microfilms International A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor, Ml 48106-1346 USA 313/761-4700 800/521-0600 Order Number 9427799 Part 1: Design, synthesis and biological activities2-(4 of -isothiocyanatobenzyl)imidazoline analogues in rat and bovine tissues.
    [Show full text]
  • Mapping Kainate Activation of Inner Neurons in the Rat Retina
    Research Article The Journal of Comparative Neurology Research in Systems Neuroscience DOI 10.1002/cne.23305 Mapping kainate activation of inner neurons in the rat retina Lisa Nivison‐Smith1, Daniel Sun2,3, Erica L. Fletcher4, Robert E. Marc5, and Michael Kalloniatis1,3,4,6 1School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, 2052, Australia; 2Department of Ophthalmology, Massachusetts Eye & Ear Infirmary, Boston, 02114, Massachusetts, United States; 3Department of Optometry and Vision Science, University of Auckland, Auckland, 1142, New Zealand; 4Department of Anatomy and Neuroscience, University of Melbourne, Parkville, 3010, Australia; 5University of Utah School of Medicine, Department of Ophthalmology, University of Utah, Salt Lake City, 84113, Utah, United States; 6Centre for Eye Health, Sydney, New South Wales, 2052, Australia. Correspondence: Professor Michael Kalloniatis, Centre for Eye Health, University of New South Wales, Sydney, 2052, NSW, Australia. Phone: Int +61 2 81150710 Fax: Int +61 2 81150799 E‐mail: [email protected] Running title: Kainate activation of rat inner retinal neurons Key words: kainate, kainate receptors, agmatine, AGB, rat retina, glutamate, GABA, glycine, immunocytochemistry This work was supported in part by research grants from the National Health and Medical Research Council of Australia [#1009342 (MK, ELF), #1021042 (ELF, MK)] and from the National Institutes of Health [#EY02576, EY014800 (REM)]. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1002/cne.23305 © 2013 Wiley Periodicals, Inc.
    [Show full text]
  • Functional Impact of Interacting Protein on Kainate Receptors: Necab1 and Neto Proteins
    Instituto de Neurociencias de Alicante Universidad Miguel Hernandez Thesis manuscript for: PhD in Neuroscience Functional impact of interacting protein on kainate receptors: NeCaB1 and NeTo proteins. Jon Palacios Filardo Supervised by: Prof. Juan Lerma Alicante, 2014 Agradecimientos/Acknowledgments Agradecimientos/Acknowledgments Ahora que me encuentro escribiendo los agradecimientos, me doy cuenta que esta es posiblemente la única sección de la tesis que no será corregida. De manera que los escribiré tal como soy, tal vez un poco caótico. En primer lugar debo agradecer al profesor Juan Lerma, por la oportunidad que me brindó al permitirme realizar la tesis en su laboratorio. Más que un jefe ha sido un mentor en todos estos años, 6 exactamente, en los que a menudo al verme decía: “Jonny cogió su fusil”, y al final me entero que es el título de una película de cine… Pero aparte de un montón de anécdotas graciosas, lo que guardaré en la memoria es la figura de un mentor, que de ciencia todo lo sabía y le encantaba compartirlo. Sin duda uno no puede escribir un libro así (la tesis) sin un montón de gente alrededor que te enseña y ayuda. Como ya he dicho han sido 6 años conviviendo con unos maravillosos compañeros, desde julio de 2008 hasta presumiblemente 31 de junio de 2014. De cada uno de ellos he aprendido mucho; técnicamente toda la electrofisiología se la debo a Ana, con una paciencia infinita o casi infinita. La biología molecular me la enseñó Isa. La proteómica la aprendí del trío Esther-Ricado-Izabella. Joana y Ricardo me solventaron mis primeras dudas en el mundo de los kainatos.
    [Show full text]
  • Product Update Price List Winter 2014 / Spring 2015 (£)
    Product update Price list winter 2014 / Spring 2015 (£) Say to affordable and trusted life science tools! • Agonists & antagonists • Fluorescent tools • Dyes & stains • Activators & inhibitors • Peptides & proteins • Antibodies hellobio•com Contents G protein coupled receptors 3 Glutamate 3 Group I (mGlu1, mGlu5) receptors 3 Group II (mGlu2, mGlu3) receptors 3 Group I & II receptors 3 Group III (mGlu4, mGlu6, mGlu7, mGlu8) receptors 4 mGlu – non-selective 4 GABAB 4 Adrenoceptors 4 Other receptors 5 Ligand Gated ion channels 5 Ionotropic glutamate receptors 5 NMDA 5 AMPA 6 Kainate 7 Glutamate – non-selective 7 GABAA 7 Voltage-gated ion channels 8 Calcium Channels 8 Potassium Channels 9 Sodium Channels 10 TRP 11 Other Ion channels 12 Transporters 12 GABA 12 Glutamate 12 Other 12 Enzymes 13 Kinase 13 Phosphatase 14 Hydrolase 14 Synthase 14 Other 14 Signaling pathways & processes 15 Proteins 15 Dyes & stains 15 G protein coupled receptors Cat no. Product name Overview Purity Pack sizes and prices Glutamate: Group I (mGlu1, mGlu5) receptors Agonists & activators HB0048 (S)-3-Hydroxyphenylglycine mGlu1 agonist >99% 10mg £112 50mg £447 HB0193 CHPG Sodium salt Water soluble, selective mGlu5 agonist >99% 10mg £59 50mg £237 HB0026 (R,S)-3,5-DHPG Selective mGlu1 / mGlu5 agonist >99% 10mg £70 50mg £282 HB0045 (S)-3,5-DHPG Selective group I mGlu receptor agonist >98% 1mg £42 5mg £83 10mg £124 HB0589 S-Sulfo-L-cysteine sodium salt mGlu1α / mGlu5a agonist 10mg £95 50mg £381 Antagonists HB0049 (S)-4-Carboxyphenylglycine Competitive, selective group 1
    [Show full text]
  • Dual Roles of Astrocytes in Plasticity and Reconstruction After Traumatic
    Zhou et al. Cell Communication and Signaling (2020) 18:62 https://doi.org/10.1186/s12964-020-00549-2 REVIEW Open Access Dual roles of astrocytes in plasticity and reconstruction after traumatic brain injury Yunxiang Zhou1†, Anwen Shao2*†, Yihan Yao1, Sheng Tu3, Yongchuan Deng1 and Jianmin Zhang2 Abstract Traumatic brain injury (TBI) is one of the leading causes of fatality and disability worldwide. Despite its high prevalence, effective treatment strategies for TBI are limited. Traumatic brain injury induces structural and functional alterations of astrocytes, the most abundant cell type in the brain. As a way of coping with the trauma, astrocytes respond in diverse mechanisms that result in reactive astrogliosis. Astrocytes are involved in the physiopathologic mechanisms of TBI in an extensive and sophisticated manner. Notably, astrocytes have dual roles in TBI, and some astrocyte-derived factors have double and opposite properties. Thus, the suppression or promotion of reactive astrogliosis does not have a substantial curative effect. In contrast, selective stimulation of the beneficial astrocyte- derived molecules and simultaneous attenuation of the deleterious factors based on the spatiotemporal- environment can provide a promising astrocyte-targeting therapeutic strategy. In the current review, we describe for the first time the specific dual roles of astrocytes in neuronal plasticity and reconstruction, including neurogenesis, synaptogenesis, angiogenesis, repair of the blood-brain barrier, and glial scar formation after TBI. We have also classified astrocyte-derived factors depending on their neuroprotective and neurotoxic roles to design more appropriate targeted therapies. Keywords: Astrocyte, Traumatic brain injury, Reconstruction, Neurogenesis, Blood-brain barrier, Glial scar Background of TBI made in the past few decades, few effective ther- Traumatic brain injury (TBI) refers to a sudden trauma apies for TBI are available [6–8].
    [Show full text]
  • Neuroscience Products
    Neuroscience Products CATALOG CATALOG NUMBER U.S. $ NUMBER U.S. $ -A- 3-(N-ACETYLAMINO)-5-(N-DECYL-N- 1 mg 27.50 159549 METHYLAMINO)BENZYL ALCOHOL 5 mg 89.40 o A23187 0-5 C [103955-90-4] (ADMB) See: Antibiotic A23187 A Protein Kinase C activator. Ref.: Proc. Nat. Acad. Sci. USA, 83, 4214 AA-861 20 mg 72.70 (1986). 159061 Purity: 95% 100 mg 326.40 C20H34N2O2 MW 334.5 0oC Orally active, specific and potent inhibitor of 5-lipoxygenase. N-ACETYL-ASP-GLU 25 mg 45.00 153036 [3106-85-2] 100 mg 156.00 Ref.: 1. Yoshimoto, T., et.al., Biochim. o Biophys. Acta, 713, 470 (1982). 2. Ashida, -20-0 C An endogenous neuropeptide with high 250 mg 303.65 Y., et.al., Prostaglandins, 26, 955 (1983). 3. affinity for a brain "Glutamate" receptor. Ancill, R.J., et.al., J. Int. Med. Res., 18, 75 Ref: Zaczek, R., et al., Proc. Natl. Acad. (1990). Sci. (USA), 80, 1116 (1983). C21H26O3 MW 326.4 C11H16N2O8 MW 304.3 ABL PROTEIN TYROSINE KINASE 250 U 47.25 N-ACETYL-2-BENZYLTRYPTAMINE 195876 (v-abl) 1 KU 162.75 See: Luzindole -70oC Recombinant Expressed in E. coli ACETYL-DL-CARNITINE 250 mg 60.00 A truncated form of the v-abl protein 154690 [2504-11-2] 1 g 214.00 tyrosine kinase which contains the 0oC Hydrochloride minimum region needed for kinase activity Crystalline and fibroblast transformation. Suppresses C9H17NO4 • HCl MW 239.7 apoptosis and induces resistance to anti-cancer compounds. O-ACETYL-L-CARNITINE CHLORIDE 500 mg 11.45 Activity: 100 KU/ml 159062 [5080-50-2] 1 g 20.65 Unit Definition: one unit is the amount of 0-5oC (R-(-)-2-Acetyloxy-3-carboxy-N,N,N-trimethyl 5 g 97.45 enzyme which catalyzes the transfer of 1 -1-propanaminium chloride) pmol of phosphate to EAIYAAPFAKKK per Purity: >88% minute at 30°C, pH 7.5.
    [Show full text]
  • Esculetin Inhibits N-Methyl-D-Aspartate Neurotoxicity Via Glutathione Preservation in Primary Cortical Cultures
    Lab Anim Res 2011: 27(3), 259-263 http://dx.doi.org/10.5625/lar.2011.27.3.259 Letter Esculetin inhibits N-methyl-D-aspartate neurotoxicity via glutathione preservation in primary cortical cultures Chang-Ryul Lee1, Eun-Joo Shin2, Hyoung-Chun Kim2, Yeon-Sik Choi3, Taekyun Shin4, Myung-Bok Wie1* 1College of Veterinary Medicine and Institute of Animal Medicine, Kangwon National University, Chuncheon, Korea 2Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Chuncheon, Korea 3Department of Laboratory Animal Science, Korea Bio Polytechnic College, Nonsan, Korea 4Department of Veterinary Medicine, Cheju National University, Jeju, Korea Recently, loss of endogenous glutathione during N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxic injury, and the resultant overproduction of reactive oxygen species (ROS) through an arachidonic acid cascade process in brain, have been implicated in neuronal damage in various neurodegenerative diseases. Glutathione depletion induced by L-buthionine-(S,R)-sulfoximine (BSO), an inhibitor of glutathione synthesis, is known to cause arachidonic acid-mediated excitotoxicity in primary mixed cortical cultures. The aim of this study was to investigate whether esculetin (6,7-dihydroxy- coumarin), an inhibitor of lipoxygenase, protects against neurotoxicity induced by NMDA or BSO. We observed that neurotoxicity induced by NMDA but not kainic acid was attenuated by esculetin. At the same concentration (100 µM), esculetin attenuated the 45Ca2+ uptake elevation induced by NMDA. Free radical-mediated neuronal injury induced by H2O2 and xanthine/xanthine oxidase was concentration- dependently blocked by esculetin. Esculetin (1-30 µM) dose-dependently inhibited BSO-induced neuronal injury. In addition, arachidonate-induced neurotoxicity was completely blocked by esculetin.
    [Show full text]